The HIVconsv Vaccines Induce Polyfunctional and Highly Proliferative T Cells that Control In Vitro HIV Replication: HIV-CORE002 Phase-I Clinical Trial

Ítems similars

• Phase I Clinical Trial HIV-CORE002 of a Universal T-cell Vaccine: One Year Follow On and Epitope Mapping
  per: Borthwick, N, et al.
  Publicat: (2013)
• Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice.
  per: Ondondo, B, et al.
  Publicat: (2013)
• Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice
  per: Ondondo, B, et al.
  Publicat: (2013)
• Targeting HIV-1 Where It Hurts
  per: Ahmed, T, et al.
  Publicat: (2013)
• Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects
  per: Hancock, G, et al.
  Publicat: (2017)